Suppr超能文献

在大鼠中,用N-乙酰半胱氨酸与甘草酸、水飞蓟宾或螺内酯联合预处理后对乙酰氨基酚及其葡糖苷酸药代动力学特征的影响。

Changes in pharmacokinetic profiles of acetaminophen and its glucuronide after pretreatment with combinations of N-acetylcysteine and either glycyrrhizin, silibinin or spironolactone in rat.

作者信息

Xu Ruijuan, Wang Qian, Zhang Jing, Zang Min, Liu Xiaoquan, Yang Jin

机构信息

Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University , Nanjing , China.

出版信息

Xenobiotica. 2014 Jun;44(6):541-6. doi: 10.3109/00498254.2013.858849. Epub 2013 Nov 19.

Abstract
  1. The present study was to investigate the effects of giving N-acetylcysteine (NAC) alone and in combination with either glycyrrhizin (GL), silibinin (SIB) or spironolactone (SL) on the plasma pharmacokinetic (PK) profiles, hepatic exposure, biliary excretion and urinary excretion of acetaminophen (APAP) and its major metabolite, acetaminophen glucuronide (AG). 2. Groups of rats (n = 5) were pretreated with oral doses of either NAC, NAC + GL, NAC + SIB or NAC + SL on five occasions every 12 h. At 1 h, after the last dose, they received APAP (200 mg/kg) by intraperitoneal injection. Blood, bile, liver and urine samples were collected at various times after APAP injection and analyzed for APAP and AG by HPLC. NAC alone and NAC + SIB did not significantly change the PK profiles of APAP and AG. In contrast, NAC + GL decreased the biliary excretion of APAP and AG leading to accumulation of APAP in the liver and systemic circulation whereas NAC + SL [multidrug resistance associated 2 (Mrp2) inducer] increased the biliary excretion of AG and decreased the hepatic exposure to APAP and AG. 3. Our results suggest that Mrp2 inhibitor GL should be discouraged with NAC to treat APAP hepatotoxicity. Such PK drug-drug interactions should be considered in the treatment of APAP-induced liver injury.
摘要
  1. 本研究旨在探究单独给予N-乙酰半胱氨酸(NAC)以及将其与甘草酸(GL)、水飞蓟宾(SIB)或螺内酯(SL)联合使用时,对乙酰氨基酚(APAP)及其主要代谢产物对乙酰氨基酚葡萄糖醛酸苷(AG)的血浆药代动力学(PK)特征、肝脏暴露量、胆汁排泄及尿液排泄的影响。2. 将大鼠分为几组(每组n = 5),每12小时口服给予NAC、NAC + GL、NAC + SIB或NAC + SL五次。在最后一剂给药后1小时,通过腹腔注射给予它们APAP(200mg/kg)。在APAP注射后的不同时间点采集血液、胆汁、肝脏和尿液样本,并通过高效液相色谱法分析其中的APAP和AG。单独使用NAC以及NAC + SIB并未显著改变APAP和AG的PK特征。相比之下,NAC + GL降低了APAP和AG的胆汁排泄,导致APAP在肝脏和体循环中蓄积,而NAC + SL[多药耐药相关蛋白2(Mrp2)诱导剂]增加了AG的胆汁排泄,并降低了肝脏对APAP和AG的暴露量。3. 我们的研究结果表明,不应将Mrp2抑制剂GL与NAC联合用于治疗APAP肝毒性。在治疗APAP诱导的肝损伤时,应考虑此类PK药物-药物相互作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验